- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Biosimilar War Is Not Over Yet
Will Sandoz' biosimilar, first ever in the US, ever see the light of day?
While Sandoz was granted regulatory approval for it's Zarxio biosimliar, filgrastim-sndz, back in March, the product has not yet reached the market...and may not for a while if Amgen has it's way.
Amgen's Neupogen, approved by FDA in 1991, is a therapy to help increase cancer patients’ white blood cell counts and fight infections. The drug, which costs approximately $3000 for each chemotherapy cycle, generated $839 million in US sales last year for Amgen. Amgen is fighting to prevent Novartis AG, the parent company of Sandoz, from marketing the product, citing copyright issues with biologic manufacturing.
Arguments from both sides were heard in a Washington appeals court yesterday.
Read more on Bloomberg: http://bloom.bg/1Qabmy0
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
